KENILWORTH (NJ) (dpa-AFX) - Korea's Hanmi Pharmaceutical said it has entered
into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc.
(MRK).

As per the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial
to evaluate the safety and efficacy of its immuno-oncology drug, 'BH3120', in
combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in
patients with progressive or metastatic solid tumors. Hanmi Pharmaceutical will
sponsor the clinical trial, and Merck will supply Keytruda.

BH3120' is a next-generation immunotherapy drug that applies 'Pentambody', a
bispecific antibody platform technology, currently under joint development by
Hanmi Pharmaceutical and its Chinese subsidiary, Beijing Hanmi Pharmaceutical.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX